ERBB2 and breast carcinoma: A breakthrough in the treatment of human epidermal growth factor receptor 2 (HER2) positive breast cancer patients was achieved by the discovery of tyrosine kinases (RTKs) inhibitors targeting protein phosphorylation, namely, trastuzumab and gefitinib [39–41].